anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To prepare a useful antiphlogistic and analgesic agent having suppressed side effects such as gastrointestinal disorder, without lowering the main effect of a non-steroid antiphlogistic and analgesic substance, by compounding a non-steroid antiphlogistic and analgesic substance and a 2,3-butanediol diester derivative as active components. CONSTITUTION:A non-steroid antiphlogistic and analgesic substance (e.g. indomethacin, aspirin, phenylbutazone, etc.) and a 2,3-butanediol diester derivative of formulaI(R1 and R2 are alkyl, alkenyl or group of formula II; R3 is H, alkyl, or cyano; R4 is phenyl, etc.) are used as active components, and mixed properly with a diluent such as starch, a binder such as sodium carboxymethylcellulose, etc. The amount of butanediol diester is preferably >=0.1pt., especially 1-20pts. per 1pt. of the non-steroid antiphlogistic and analgesic substance.
The disclosure relates to isolated polynucleotides and purified polypeptides of the Neu family of proteins, which have been shown to demonstrate transcriptional regulatory activity. For example, the purified polynucleotide can encode a Neu polypeptide, wherein the Neu polypeptide comprises at least one neuralized homology repeat domain and a C3HC4 RING-zinc finger domain is disclosed. A purified Neu polypeptide, wherein the Neu polypeptide comprises at least one neuralized homology repeat domain and a C3HC4 RING-zinc finger domain is disclosed. Antibodies capable of specifically binding to the disclosed Neu polypeptides are disclosed. Vectors expressing the disclosed Neu protein coding regions and host cells containing the vectors are disclosed.  Methods of making the Neu proteins disclosed are also provided, as are method of identifying binding partners that interact with a Neu protein family member.
Group A will receive Placebo Oral Capsule 2 times a day for a total of 14 days. On Day 14 they will have a Magnetic Resonance Imaging (MRI) exam. They will then have a 14 day washout period. They will then receive NAC 2 times a day for 14 days and have another MRI exam on day 14.
OBJECTIVES: Circular RNAs (circRNAs) serve a crucial regulatory role in ovarian cancer (OC). Circular RNA ArfGAP with FG repeats 1 (circAGFG1) has been shown to be involved in promoting the progression of several cancers, containing triple-negative breast cancer, esophageal cancer and colorectal cancer. However, the function of circAGFG1 in OC is unclear.
METHODS: Quantitative real-time reverse transcription PCR (RT-qPCR) was conducted to determine the expression levels of circAGFG1 and miR-409-3p. The proliferation and metastasis of cells were determined by colony formation assays, EdU assays, transwell assays and wound healing assays. In addition, a dual-luciferase reporter assay was performed to validate the mechanism between circAGFG1, miR-409-3p, and ZEB1.
RESULTS: Our data suggested that circAGFG1 was significantly overexpressed in OC tissues compared to normal ovarian epithelial tissues. Overexpression of circAGFG1 was correlated with intraperitoneal metastasis, tumor recurrence and advanced stage. Additionally, circAGFG1 overexpression revealed a poor prognosis in OC patients. Knockdown of circAGFG1 suppressed the proliferation, invasion and migration of OC cells. Mechanistically, circAGFG1 acted as a sponge of miR-409-3p to enhance the expression level of zinc finger E-box binding homeobox 1 (ZEB1), thereby conferring OC cell proliferation, invasion and migration. Importantly, re-expression of ZEB1 effectively reversed the effects of circAGFG1 knockdown on OC cells.
CONCLUSIONS: In summary, our study indicated that circAGFG1 may act as a prognostic biomarker and potential therapeutic target for patients with OC.
Protein tyrosine phosphatase 1B (PTP1B) is a non-receptor tyrosine phosphatase best known for its role in regulating insulin and leptin signalling. Recently, knowledge on the role of PTP1B as a major regulator of multiple signalling pathways involved in cell growth, proliferation, viability and metabolism has expanded, and PTP1B is recognised as a therapeutic target in several human disorders, including diabetes, obesity, cardiovascular diseases and hematopoietic malignancies. The function of PTP1B in the immune system was largely overlooked until it was discovered that PTP1B negatively regulates the Janus kinase-a signal transducer and activator of the transcription (JAK/STAT) signalling pathway, which plays a significant role in modulating immune responses. PTP1B is now known to determine the magnitude of many signalling pathways that drive immune cell activation and function. As such, PTP1B inhibitors are being developed and tested in the context of inflammation and autoimmune diseases. Here, we provide an up-to-date summary of the molecular role of PTP1B in regulating immune cell function and how targeting its expression and/or activity has the potential to change the outcomes of immune-mediated and inflammatory disorders.
Aqueous pharmaceutical substance for local application to the eye, consisting essentially of an ophthalmic agent and 0.1-5.0 wt.% (based on the substance) of microcrystalline collagen. The microcrystalline collagen improves the pharmacological action of the ophthalmic agent and/or prolongs the duration of its therapeutic effect. Numerous examples of ophthalmic agents are listed in the specification, typical being carbachol, pilocarpine salts, epinephrine salts, dexamethasone, phenylbutazone, sulphacetamide, hydrocortisone, chlorbutanol, prednisolone acetate, phenylephrine HCl, tropicamide, ZnSO4, polymyxin B sulphate, neomycin sulphate, atropine sulphate and triamcinolone acetamide. A suitable microcrystalline collagen is marketed under the name "Avitene) (RTM) by FMC Corp. The pharmaceutical substance can take the form of an aqueous dispersion, or of a salve or semi-solid or gel-like composition. A suitable composition contains 0.003-1% carbachol; HCl (0.01M) to pH 3.5; 0.5% microcrystalline collagen and water q.s.
Back ground: Pulmonary vein antrum isolation (PVAI) as a lone procedure, is known to have limited success rate in terms of long-term recurrence-free survival in non-paroxysmal atrial fibrillation (NPAF) and additional ablations isolating extra-PV triggers seem to improve the outcome (1). The extra-PV triggers include triggers from other sites such as left atrial posterior wall, superior vena cava, interatrial septum, crista terminalis, left atrial appendage and coronary sinus (1, 2). These are known to be independent predictors of late AF recurrence following catheter ablation (3, 4, and 5). Earlier studies have demonstrated better ablation outcome in NPAF when non-PV triggers sites were isolated along with PVAI (5, 6). Moreover, Verma et al had reported high (57%) recurrence rate post-index procedure in AF patients with pre-existent scar (7). However, published data are conflicting regarding the benefits of additional substrate guided ablation (scar homogenization) compared to conventional PVAI alone strategy (8). Also, limited data is available showing a comparison of the lasting efficacy of the above three procedures when used in different combinations.

Hypothesis: The combined ablation strategy including PVAI, scar homogenization and ablation of extra-PV triggers has the highest likelihood of maintaining long-term sinus rhythm in patients with NPAF.
Participants receive oral selenium yeast daily for 6 months. Treatment repeats every 6 months for 8 courses for a total of 4 years in the absence of unacceptable toxicity.
Hydroxyurea is a human carcinogen. In patients receiving long-term hydroxyurea for myeloproliferative disorders, secondary leukemia has been reported. 

Secondary leukemia has also been reported in patients treated with long-term hydroxyurea for sickle cell disease. Leukemia has also been reported in patients with sickle cell disease and no prior history of treatment with hydroxyurea. 

All patients using DROXIA should be followed up on a long-term basis with regular blood counts to detect development of leukemia. 

Skin cancer has also been reported in patients receiving long-term hydroxyurea. Advise protection from sun exposure and monitor for the development of secondary malignancies.
Ciprofloxacin is moderate inhibitor of cytochrome P450 1A2 (CYP1A2), one of the enzymes responsible for the metabolism of quinine. This study will evaluate the effect of ciprofloxacin-related inhibition of CYP1A2 on the pharmacokinetics of quinine sulfate. In the morning on study Day 1 after a fast of at least 10 hours, twenty-four healthy, non-smoking, non-obese, non-pregnant adult volunteers between the ages of 18 and 45 will be given one oral dose of quinine sulfate (2 x 324 mg capsules). Fasting will continue for 4 hours after the dose. Blood samples will be drawn from all participants before dosing and for 36 hours post-dose at times sufficient to adequately define the pharmacokinetics of quinine sulfate. A 7-day washout period will be completed after the first dose of quinine sulfate on Day 1. Beginning at 07:45 am on Day 8 and continuing through Day 10, all subjects will return to the clinic for non-confined dosing of ciprofloxacin (1 x 500 mg tablet) every 12 hours. Administered ciprofloxacin doses on these days will not be in a fasted state. At 07:45 am on Day 11 after a fast of at least 10 hours, all study participants will receive a co-administered single oral dose of quinine sulfate (2 x 324 mg capsules) and ciprofloxacin (1 x 500 mg tablet). A final dose of ciprofloxacin (1 x 500 mg tablet) will be administered 12 hours later. Blood samples will be drawn from all participants before dosing and for 36 hours post-dose at times sufficient to adequately define the pharmacokinetics of quinine sulfate. Fasting will continue for 4 hours following the co-administered dose of quinine sulfate and ciprofloxacin. A further goal of this study is to evaluate the safety and tolerability of this regimen in healthy volunteers. Subjects will be monitored throughout participation in the study for adverse reactions to the study drug and/or procedures. Seated blood pressure and pulse will be measured pre-dose and at 1, 2 and 3 hours post-dose on Days 1 and 11. An electrocardiogram (ECG) will be done pre-dose and at 1, 2 and 4 hours post-dose on Days 1 and 11. All adverse events whether elicited by query, spontaneously reported, or observed by clinic staff will be evaluated by the Investigator and reported in the subject's case report form.
PROBLEM TO BE SOLVED: To obtain a nasal liquid drop useful for treatment of head cold and its accompanying symptom, caused by allergy, vasomotor nerve and nasal virus, and having improved compatibility by including a specific proportion of azelastine and not including hydroxypropylmethylcellulose. SOLUTION: This nasal liquid drop contains 0.0005-2% (wt./wt.) azelastine allowed to be present in a form of physiologically compatible salt, and does not contain hydroxypropylcellulose. The preparation preferably contains 0.001-0.1% (wt. per vol. of a solution when the preservative is the solution) pharmaceutically acceptable preservative (preferably an alkylbenzyldimethylammonium chloride or the like). The dose to a nostril is preferably 0.05-0.15 ml, and 1-5 time doses of the amount per day are preferable.
BACKGROUND: Enterococcus faecium is a Gram-positive bacterium, naturally present in the human intestinal microbiota, but is also an opportunistic pathogen responsible for healthcare-associated infections. Persisters are individuals of a subpopulation able to survive by arrest of growth coping with conditions that are lethal for the rest of the population. These persistent cells can grow again when the stress disappears from their environment and can cause relapses.
RESULTS: In this study, we highlighted that ciprofloxacin (10-fold the MIC) led to the formation of persister cells of E. faecium. The kill curve was typically biphasic with an initial drop of survival (more than 2 orders of magnitude reduction) followed by a constant bacterial count. Growth curves and antimicrobial susceptibility tests of these persisters were similar to those of the original cells. In addition, by genomic analyses, we confirmed that the persisters were genotypically identical to the wild type. Comparative proteomic analysis revealed that 56 proteins have significantly different abundances in persisters compared to cells harvested before the addition of stressing agent. Most of them were related to energetic metabolisms, some polypeptides were involved in transcription regulation, and seven were stress proteins like CspA, PrsA, ClpX and particularly enzymes linked to the oxidative stress response.
CONCLUSIONS: This work provided evidences that the pathogen E. faecium was able to enter a state of persister that may have an impact in chronic infections and relapses. Moreover, putative key effectors of this phenotypical behavior were identified by proteomic approach.
Patients receive fluorouracil IV continuously on days 1-7 and 15-21 and recombinant interferon alpha 2b-like protein SC on days 1, 3, 5, 15, 17, and 19. Treatment repeats every 28 days for 2 cycles in the absence of disease progression or unacceptable toxicity. Beginning in cycle 3, patients receive nivolumab IV over 30 minutes on day 1, fluorouracil IV continuously on days 1-7 and 15-21, and recombinant interferon alpha 2b-like protein interferon alpha 2b SC on days 1, 3, 5, 15, 17, and 19. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
Patient with Metavir score between F1 and F4 will be assigned to the case group. Collected data will contain epidemiological and biological data, blood samples with chlordecone dosage.
BACKGROUND: This study evaluated parenting stress, anxiety, and depression symptoms and their associated factors in parents of children with chronic kidney disease (CKD).
METHODS: This cross-sectional study compared parents of patients with CKD (0-18 years) with a matched control group of parents of healthy children. Both groups completed the Parenting Stress Index - Short Form, the Hospital Anxiety and Depression Scale, and a sociodemographic questionnaire.
RESULTS: The study group consisted of 45 parents (median age 39; 32 mothers) of CKD patients (median age 8; 36% female). Nearly 75% of children had CKD stages 2, 3, or 4, and 44.5% had congenital anomaly of the kidney and urinary tract. Five children (11%) were on dialysis, and 4 (9%) had a functioning kidney graft. Compared with parents of healthy children, more stress and anxiety symptoms were reported. Since the CKD diagnosis, 47% of parents perceived a deterioration of their own health, and 40% reduced work on a structural basis. Higher levels of stress, anxiety, and depression symptoms were associated with a more negative perception of own health, and more child medical comorbidities and school absence.
CONCLUSIONS: This study showed higher levels of parenting stress and anxiety symptoms in parents of children with CKD compared with parents of healthy children. This was associated with a less positive perception of their own health, especially if the child had more medical comorbidities or more absence from school. Psychosocial interventions to reduce the parental burden should be integrated in the standard care of pediatric nephrology departments.
A light activated collagen-flavin composite layer incorporating riboflavin is applied as treatment for infected lesions caused by bacteria and as the consequence of surgical procedures. These composites have also been found to be strong tissue adhesives that are effective in closing and sealing wounds, fixation of grafts/implants and anastomoses. Advantages include speed of closure, reduced infection due to the elimination of foreign matter, evidence of accelerated wound healing and the ease of use in complex surgery, especially when watertight seals, limited access or small repair size are important factors. The riboflavin in the collagen layer is exposed to light (e.g., light having a wavelength between 360-375 nm or 440-480 nm), decomposing the riboflavin to form reactive oxygen species (ROS). Strong crosslinks between the collagen composite and tissue results. In addition, similar exposures eradicate pathogens in the wound is eradicated resulting in a sterile wound. In other examples, the composite film may instead contain lumichrome or lumiflavin.
The NIH provides a unique opportunity for research scientists to participate in the bench-to-bedside process, which is essential for the full implementation of translational medicine programs. The study of rare monogenetic and undiagnosed diseases is a complex bedside-to-bench-to-bedside endeavor. Recent studies show that rare genetic variants are more likely than common variants to have deleterious effects on protein structure, function, and/or expression, possibly leading to clinically relevant events. Studies of large patient populations offer the opportunity to identify rare genetic variants underlying human disease and will have impactful implications for human health. We propose to characterize the etiology and natural history of rare and orphan diseases with vascular phenotypes. We will also study rare genetic modifiers and identify novel disease mechanisms contributing to common vascular diseases. Subsequent disease-related protocols may be developed based on findings from subjects enrolled in this protocol for further intensive natural history studies and potential innovative therapeutic studies. In addition to its role in investigating individuals who are of interest to the Translational Vascular Medicine Branch (TVMB) of the NHLBI, this protocol can provide a possible avenue for admitting subjects from other NIH programs, such as the NIH Undiagnosed Diseases Program, the Center for Human Immunology Trans-institute program or other NIH protocols where subjects exhibit vascular phenotypes.
Contrast induced nephropathy (CIN) is a common cause of renal failure associated with prolonged hospitalization, significant morbidity or mortality, and cost. CIN has been reported to account for 10% of hospital acquired renal failure. Several strategies or medications were tried to prevent CIN. Of these, mucomyst and normal saline infusion are effective to prevent CIN. Sodium bicarbonate has shown mixed results from recent randomized trials. Moreover,limited data have been available for preventing CIN in diabetic renal dysfunction undergoing coronary angiography or intervention. Our hypothesis is that addition of sodium bicarbonate will be more efficacious than normal saline in preventing CIN at above situation.
The control group will be asked to abstain from intervention activities during the 8 week period. The control group will receive the delayed 8-week intervention one year after the intervention group.
Autophagy, a conserved cellular degradation process, is crucial for various cellular processes such as immune responses, inflammation, metabolic and oxidative stress adaptation, cell proliferation, development, and tissue repair and remodeling. Dysregulation of autophagy is suspected in numerous diseases, including cancer, neurodegenerative diseases, digestive disorders, metabolic syndromes, and infectious and inflammatory diseases. If autophagy is disrupted, for example, this can have serious consequences and lead to chronic inflammation and tissue damage, as occurs in diseases such as Chron's disease and ulcerative colitis. On the other hand, the influence of autophagy on the development and progression of cancer is not clear. Autophagy can both suppress and promote the progression and metastasis of cancer at various stages. From inflammatory bowel diseases to gastrointestinal cancer, researchers are discovering the intricate role of autophagy in maintaining gut health and its potential as a therapeutic target. Researchers should carefully consider the nature and progression of diseases such as cancer when trying to determine whether inhibiting or stimulating autophagy is likely to be beneficial. Multidisciplinary approaches that combine cutting-edge research with clinical expertise are key to unlocking the full therapeutic potential of autophagy in digestive diseases.
The invention discloses a preparing method of polypeptide hydrogel. The method includes dissolving polypeptide into a dispersing medium to form a polypeptide solution, and then the polypeptide hydrogel can be formed after several minutes. The polypeptide is formed by n repeated xKEALKEy amino acid sequences, wherein the n is an integer from 2 to 10, the x is a hydrophobic amino acid, the y is a hydrophilic amino acid, the K is lysine, the E is glutamic acid, the A is alanine and the L is leucine. The polypeptide hydrogel and applications thereof are also disclosed by the invention. The preparing method is simple and convenient in operation, components of the polypeptide hydrogel are pure and controllable and the main folding manner of the polypeptide used in the method is an alpha spiral manner, thus avoiding possible safety problems fundamentally. The polypeptide hydrogel prepared by the method can maintain a gel state in a pH range of 5.8-7.6, and is liquid when a pH value is out of the range.
Accurate seizure and epilepsy diagnosis remains a challenging task due to the complexity and variability of manifestations, which can lead to delayed or missed diagnosis. Machine learning (ML) and artificial intelligence (AI) is a rapidly developing field, with growing interest in integrating and applying these tools to aid clinicians facing diagnostic uncertainties. ML algorithms, particularly deep neural networks, are increasingly employed in interpreting electroencephalograms (EEG), neuroimaging, wearable data, and seizure videos. This review discusses the development and testing phases of AI/ML tools, emphasizing the importance of generalizability and interpretability in medical applications, and highlights recent publications that demonstrate the current and potential utility of AI to aid clinicians in diagnosing epilepsy. Current barriers of AI integration in patient care include dataset availability and heterogeneity, which limit studies' quality, interpretability, comparability, and generalizability. ML and AI offer substantial promise in improving the accuracy and efficiency of epilepsy diagnosis. The growing availability of diverse datasets, enhanced processing speed, and ongoing efforts to standardize reporting contribute to the evolving landscape of AI applications in clinical care.
In the stepped wedge experimental design, 40 participants at any time during the 2 year study are receiving only the Behavioral Health Home (BHH) intervention. The 2010 Patient Protection and Affordable Care Act (ACA) established a "health home" option under Medicaid that serves enrollees with chronic conditions including serious mental illness and chronic physical illness.